Phase 1
Phase 2
Phase 3

A Phase 1 trial is ongoing


Our technology for generating and identifying functional human antibodies may also be applied to disease areas outside of cancer. Examples include, but are not limited to, autoimmune and infectious disease targets.

Infectious disease agents are particularly attractive for our antibody discovery platform as it allows us to tap into an ongoing or a memory immune response in human patients. Isolation of B-cells from infectious disease patients enables us to identify those antibodies that are responsible for neutralizing the disease agent and hence are aiding in patient recovery. We have extensive experience in this area and have identified large repertoires of antibodies against various viruses and bacteria.

S. aureus
Phase 1b ongoing
A randomized, double-blind, placebo-controlled, multiple-ascending dose study enrolling up to 24 patients

Clinical development of Sym009

Sym009 is a mAb conjugated to an antibiotic agent, which is being developed for the treatment of certain methicillin-resistant or methicillin-sensitive strains of staphylococcus aureus (MRSA).

The Phase 1b trial evaluates DSTA4637S, an investigational medicine containing Sym009 conjugated to an antibiotic agent. Sym009 was originally discovered by isolating antibodies from individuals exposed to S.aureus using Symphogen’s patented Symplex technology.


Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S.
Nature 527, 323–328 (2015)
Read more about our strategic partnerships